Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Gastroenterology. 2020 Oct;159(4):1541-1544.e2. doi: 10.1053/j.gastro.2020.05.066. Epub 2020 May 29.

¹ Jill Roberts Center for Inflammatory Bowel Disease, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York; Division of Gastroenterology and Hepatology, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York. Electronic address: djl9010@med.cornell.edu.
² Jill Roberts Center for Inflammatory Bowel Disease, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York.
³ Division of Gastroenterology and Hepatology, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York.
⁴ Jill Roberts Center for Inflammatory Bowel Disease, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York; Division of Gastroenterology and Hepatology, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York.
⁵ Jill Roberts Center for Inflammatory Bowel Disease, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York; Division of Gastroenterology and Hepatology, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, New York, New York.

No abstract available

Keywords: Biologic Therapy; COVID-19; IBD; SARS-CoV-2.

MeSH terms